Lifeboat Foundation

In patients with Alzheimer’s disease (AD), amyloid-β (Aβ) plaques and tau protein tangles accumulate in the brain long before the appearance of clinical symptoms. Early intervention is critical for slowing neurodegeneration and disease progression. Therefore, reliable markers of early AD are needed. Lucey et al. analyzed sleep patterns in aging cognitively normal subjects and showed that non–rapid eye movement (NREM) sleep negatively correlated with tau pathology and Aβ deposition in several brain areas. The results show that alterations in NREM sleep may be an early indicator of AD pathology and suggest that noninvasive sleep analysis might be useful for monitoring patients at risk for developing AD.

In Alzheimer’s disease (AD), deposition of insoluble amyloid-β (Aβ) is followed by intracellular aggregation of tau in the neocortex and subsequent neuronal cell loss, synaptic loss, brain atrophy, and cognitive impairment. By the time even the earliest clinical symptoms are detectable, Aβ accumulation is close to reaching its peak and neocortical tau pathology is frequently already present. The period in which AD pathology is accumulating in the absence of cognitive symptoms represents a clinically relevant time window for therapeutic intervention. Sleep is increasingly recognized as a potential marker for AD pathology and future risk of cognitive impairment. Previous studies in animal models and humans have associated decreased non–rapid eye movement (NREM) sleep slow wave activity (SWA) with Aβ deposition. In this study, we analyzed cognitive performance, brain imaging, and cerebrospinal fluid (CSF) AD biomarkers in participants enrolled in longitudinal studies of aging.

A host of companies are developing regenerative treatments that lean on stem cells. Seeing an opportunity, Japan’s Fujifilm will build a U.S. stem cell manufacturing facility not only for its own efforts but also as a CDMO.

The company said today that its Fujifilm Cellular Dynamics Inc. (FDCI) subsidiary will invest about $21 million to build a facility in Madison, Wisconsin, to “industrialize” induced pluripotent stem cell technologies for its pipeline of regenerative drugs and to manufacture iPS cells for others. It expects the facility to be ready by March 2020.

“To meet the growing demand for FCDI’s iPS cell platform, the state-of-the-art production facility will have a flexible cell culturing design to serve production requirements of both industrial quantities of cells, and small, diverse batches,” Seimi Satake, FCDI CEO, said in a statement. “By combining Fujifilm’s experience gleaned from the intricate process of manufacturing photographic film along with FCDI’s knowledge of cell reprogramming, genetic engineering and cell differentiation, the facility is poised to address the complex manufacturing processes of cell therapies.”

Continue reading “Fujifilm plans $20M U.S. facility for burgeoning interest in stem cell treatments” »

Today in the Mail’s pullout, the twins focus on anti-ageing your brain, and show you simple strategies to give it a boost — from telling you why you’re becoming forgetful to revealing the techniques you can use to improve brain health and function.

Yes, in the ‘spouse’ seat during counselling was Xand, his identical twin and fellow telly doctor.

It’s quite a revelation that these two — both contenders for the title of TV’s sexiest doctor, surely — have a relationship that might require them even to think of counselling.

Continue reading “Doctor double act can help you live healthier for longer in their anti-ageing series for the Mail” »

The new device, developed by researchers from the University of California in the US, absorbs excess drugs before they spread throughout the body.

For example, doxorubicin, a chemotherapy drug, kills more tumour cells when given at higher doses. However, most patients cannot tolerate large amounts of the drug because it can cause heart failure, among other side effects.

But using the device, excess doxorubicin can be filtered out from the blood at locations outside of the tumour to reduce the harmful effects of the drug on the healthy cells.

Continue reading “Novel Device to Reduce Chemotherapy’s Harmful Side Effects” »

Some see stem cell therapy as the future of medicine, but not all of the treatments have been proven to work. Yet the treatments cost patients tens of thousands of dollars.

NBC 7 Investigates has been looking into stem cell clinics and treatments offered across San Diego County for nearly a year. On Friday, NBC’s Today show featured NBC 7’s work in a report on stem cell treatments.

Today Show Segment on Rise in Stem Cell Clinics

Continue reading “San Diego Stem Cell Clinics in National Spotlight” »

Some Parkinson’s disease patients with a specific genetic variant have widespread reduction of gray matter in dementia-related brain regions.

Thanks so much to Luanna Helena for having me on Creatively Speaking Radio to discuss Bioquark Inc. (http://www.bioquark.com) and nature’s clues for human regeneration, disease reversion, and age rejuvenation -

Also got to introduce our new mosquito / “ectocrinome” research program — (https://www.bizjournals.com/philadelphia/news/2019/01/02/bio…nefit.html) —

http://blogtalkradio.com/creativelyspeaking/2019/01/12/episode-79-ira-pastor

A quantum computer isn’t just a more powerful version of the computers we use today; it’s something else entirely, based on emerging scientific understanding — and more than a bit of uncertainty. Enter the quantum wonderland with TED Fellow Shohini Ghose and learn how this technology holds the potential to transform medicine, create unbreakable encryption and even teleport information.

https://paper.li/e-1437691924

Bioscience and medical technology are propelling us beyond the old human limits. Are Extremes and The Posthuman good guides to this frontier?

By David Cohen

Continue reading “What does it mean to be posthuman?” »